Catalyst
Slingshot members are tracking this event:
Dynavax Technologies (DVAX) to complete Phase 1b trial of SD-101 in combination with Pembrolizumab in patients with Metastatic Melanoma in June 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| DVAX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 02, 2017
Occurred Source:
http://investors.dynavax.com/releasedetail.cfm?ReleaseID=1028885
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Metastatic Melanoma, Phase 1b Trial, Sd-101
